← Leaderboards
Levon Bostanian
Xavier University Of Louisiana
$748,432
Attributed
$748,432
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $108.5K · FY2012–20$200K$150K$100K$50K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$748,432 · 1
By mechanism
SC3$748,432 · 1
Top collaborators
No co-investigators on record.
Most similar at Xavier University Of Louisiana
Same institution · by research overlap
- Robert C Blake$2,197,800
- Levon A Bostanian$374,186
Others in their field
Top investigators on “Nanotechnology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$272,311,477
- David Heimbrook · Leidos Biomedical Research, Inc.$109,987,192
- Roger T Howe · University Of California-Berkeley$94,508,396
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Daniel C Ralph · Cornell University$90,979,534
- Leonard Freedmand · Leidos Biomedical Research, Inc.$64,603,040
Research focus
NanotechnologyOral AdministrationInnovationNanoparticleNeoplasmsOralDoseFosteringIn VitroMorphologyDrug Delivery SystemsCaco-2 CellsBaseNeuroblastomaCancer TherapyBasic ScienceEvaluationFenretinideBiological AvailabilityInterdisciplinary ApproachIn VivoChildhoodAbsorptionParticle Size
Grant awards (7)
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$107,652
SC3 · FY2020 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$107,011
SC3 · FY2019 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$106,384
SC3 · FY2018 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$105,768
SC3 · FY2017 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$108,471
SC3 · FY2014 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$104,675
SC3 · FY2013 · GM · contact PI
Formulation of Fenretinide Nanoparticles for Enhanced Bioavailability$108,471
SC3 · FY2012 · GM · contact PI